Results 171 to 180 of about 18,392,427 (194)
Some of the next articles are maybe not open access.
Histone deacetylase 3 regulates microglial function through histone deacetylation
2022Abstract Background As the primary innate immune cells of the brain microglia respond to damage and disease through pro-inflammatory release of cytokines and neuroinflammatory molecules. Histone acetylation is an activating transcriptional mark that regulates gene expression, which is altered in ...
Laura Meleady +5 more
openaire +1 more source
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
European Journal of Medicinal Chemistry, 2020Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is an epigenetic drug target which is currently marked as a potential therapeutic strategy to combat various cancers. HDAC3 inhibitors are effective for the treatment of cancers, different neurodegenerative disorders, diabetes mellitus, cardiac diseases, HIV, inflammatory ...
Rajat, Sarkar +4 more
openaire +2 more sources
Histone deacetylases 1, 2 and 3 in nervous system development
Current Opinion in Pharmacology, 2020Although histone acetylases (HDACS) were initially believed to render chromatin in a transcriptionally repressed state by deacetylating histones, it is now known that they both repress and activate transcription. Moreover, HDACs regulate the activity and/or function of a large number of other cellular proteins localized in the nucleus and cytoplasm ...
openaire +2 more sources
HDAC3_VS_assistant: cheminformatics-driven discovery of histone deacetylase 3 inhibitors
Molecular DiversityHistone deacetylase 3 (HDAC3) inhibitors keep significant therapeutic promise for treating oncological, neurodegenerative, and inflammatory diseases. In this work, we developed robust QSAR regression models for HDAC3 inhibitory activity and acute toxicity (LD50, intravenous administration in mice).
Oleg V, Tinkov, Veniamin Y, Grigorev
openaire +2 more sources
Histone Deacetylase Inhibitors as Anticancer Drugs
International Journal of Molecular Sciences, 2017Marie Stiborova +2 more
exaly
Clinical Toxicities of Histone Deacetylase Inhibitors
Pharmaceuticals, 2010Susan Bates, Igor Espinoza-Delgado
exaly